Literature DB >> 12098069

Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation.

M Aricò1, M Zecca, N Santoro, D Caselli, R Maccario, C Danesino, G de Saint Basile, F Locatelli.   

Abstract

Griscelli syndrome (GS) is a rare autosomal recessive disorder, characterized by pigmentary dilution of the skin and hair and in most patients by abnormal regulation of the immune system, which results in a syndrome of macrophage hyperactivation, known as hemophagocytic lymophohistiocytosis (HLH). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment available for genetically induced HLH. Few cases of successful HSCT from a compatible donor have been reported in children with GS. We describe the first patient with GS cured with an allograft from a compatible unrelated bone marrow donor. We used a novel preparative regimen consisting of busulfan, thiotepa and fludarabine. The demonstrated curative effect of HSCT from an unrelated donor in a patient with genetically determined HLH also supports the use of a systematic diagnostic approach in these patients, in order to identify those with a worse prognosis and needing an urgent allograft in a timely manner.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12098069     DOI: 10.1038/sj.bmt.1703567

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Analysis of RAB27A gene in griscelli syndrome type 2: novel mutations including a deletion hotspot.

Authors:  Setareh Mamishi; Mohammad Hossein Modarressi; Babak Pourakbari; Banafshe Tamizifar; Fatemeh Mahjoub; Alireza Fahimzad; Soheila Alyasin; Mohamad Hassan Bemanian; Amir Ali Hamidiyeh; Mohammad Reza Fazlollahi; Mahmoud Reza Ashrafi; Anna Isaeian; Ghamartaj Khotaei; Mehdi Yeganeh; Nima Parvaneh
Journal:  J Clin Immunol       Date:  2008-03-19       Impact factor: 8.317

2.  Griscelli syndrome types 1 and 3: analysis of four new cases and long-term evaluation of previously diagnosed patients.

Authors:  Deniz Cağdaş; Tuba Turul Ozgür; Gülten Türkkanı Asal; Ilhan Tezcan; Ayşe Metin; Nathalie Lambert; Geneiveve de Saint Basile; Ozden Sanal
Journal:  Eur J Pediatr       Date:  2012-06-19       Impact factor: 3.183

3.  Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients.

Authors:  M Al-Mofareh; M Ayas; A Al-Seraihy; K Siddiqui; A Al-Jefri; I Ghemlas; H Alsaedi; H El-Solh; S Al-Sweedan; B Al-Saud; H Al-Mousa; H Al-Dhekri; R Arnaout; R Mohammed; S Al-Muhsen; A Al-Ahmari
Journal:  Bone Marrow Transplant       Date:  2020-04-14       Impact factor: 5.483

4.  An essential role for Rab27a GTPase in eosinophil exocytosis.

Authors:  John Dongil Kim; Lian Willetts; Sergei Ochkur; Nutan Srivastava; Rudolf Hamburg; Anooshirvan Shayeganpour; Miguel C Seabra; James J Lee; Redwan Moqbel; Paige Lacy
Journal:  J Leukoc Biol       Date:  2013-08-28       Impact factor: 4.962

Review 5.  Molecular basis and therapy of disorders associated with chronic neutropenia.

Authors:  Steven M Stein; David C Dale
Journal:  Curr Allergy Asthma Rep       Date:  2003-09       Impact factor: 4.806

6.  Development, characterization, and hematopoietic differentiation of Griscelli syndrome type 2 induced pluripotent stem cells.

Authors:  Gülen Güney-Esken; Özgür Doğuş Erol; Burcu Pervin; Gülben Gürhan Sevinç; Tamer Önder; Elif Bilgiç; Petek Korkusuz; Ayşen Günel-Özcan; Duygu Uçkan-Çetinkaya; Fatima Aerts-Kaya
Journal:  Stem Cell Res Ther       Date:  2021-05-13       Impact factor: 6.832

Review 7.  Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism.

Authors:  Laura Dotta; Silvia Parolini; Alberto Prandini; Giovanna Tabellini; Maddalena Antolini; Stephen F Kingsmore; Raffaele Badolato
Journal:  Orphanet J Rare Dis       Date:  2013-10-17       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.